- Takami Taro
Affiliate Master Yamaguchi University
Id (<span class="translation_missing" title="translation missing: en.view.desc">Desc</span>)
Liquid biopsy test based on a sensitive dna methylation assay for diagnosing hepatocellular carcinoma : which is a better marker, methylated sst or sept9?
山口医学 Volume 70 Issue 3 pp. 89 - 98
We performed this study to investigate whether serum cell-free DNA testing(liquid biopsy)of either methylated SEPT9 or methylated SST, which are possible biomarkers of HCC, in combination with AFP may improve clinical performance for the detection of HCC. Study subjects included 25 healthy controls, 15 patients with chronic liver disease without HCC, and 38 patients with HCC. Methylation level of serum cell-free SEPT9 and SST was measured by methylation-sensitive restriction enzymes followed by multiplex droplet digital polymerase chain reaction. According to receiver operating characteristic curve analysis to discriminate between non-HCC group(including control group and chronic liver disease without HCC group)and HCC group, area under the curve(AUC)was 0.73 by AFP and 0.73 by mSEPT9, whereas it was only 0.59 by mSST. Regarding combination tests, although negative predictive values were almost same between the AFP + mSEPT9 test and the AFP + mSST test(75.0% vs 72.2%),a positive predictive value of AFP + mSEPT9 test was higher than that of the AFP + mSST test(79.4% vs. 66.7%).In conclusions, methylated SEPT9 was a better companion marker of AFP for HCC screening than methylated SST.
The bulletin of the Yamaguchi Medical School Volume 67 Issue 1-2 pp. 1 - 10
Utility of real-time tissue elastography in the sequential evaluation of liver fibrosis in patients with chronic hepatitis C
The bulletin of the Yamaguchi Medical School Volume 66 Issue 1-2 pp. 29 - 35
The bulletin of the Yamaguchi Medical School Volume 66 Issue 1-2 pp. 7 - 13
山口医学 Volume 66 Issue 3 pp. 163 - 168
A case of chronic hepatitis c with charcot-marie-tooth disease successfully treated with interferon beta and rivabirin combination therapy
山口医学 Volume 64 Issue 1 pp. 53 - 57
A 36-year-old man diagnosed with Charcot-Marie-Tooth(CMT)disease type 1B was treated in the department of neurology of this hospital. Due to a liver injury(AST 237IU/ml, ALT 496IU/ml)which occurred in November 200X, he was introduced to our department. As a result of scrutiny, we diagnosed him with chronic hepatitis C genotype 2a(HCV-RNA 5.4logIU/ml).He will be admitted to the hospital for Interferon(IFN)therapy in April next year. Although the mechanism is unknown, there are a few reports of peripheral neuropathy related to IFN therapy. Therefore, IFN therapy is generally unfavorable for patients with neuromuscular disorders. There are several IFN preparations used in Japan. IFN alfa associated peripheral neuropathy appears less than 0.1-5% of the time. While there is no report of peripheral neuropathy related to IFN beta, we performed IFN beta and Rivabirin combination therapy with a severe follow-up by a neurologist. We could accomplish treatment without the exacerbation of neurologic symptoms. He achieved sustained viral response. When IFN therapy was provided for chronic hepatitis B or chronic hepatitis C complicated with peripheral neuropathy, there is some possibility of performing antiviral therapy safely by using IFN beta.
Status and prospects of liver cirrhosis treatment by using bone marrow-derived cells and mesenchymal cells
Tissue engineering. Part B, Reviews Volume 20 Issue 3 pp. 206 - 210
Creators : Terai Shuji Takami Taro Yamamoto Naoki Fujisawa Koichi Ishikawa Tsuyoshi Urata Yohei Tanimoto Haruko Iwamoto Takuya Mizunaga Yuko Matsuda Takashi Oono Takashi Marumoto Miho Burganova Guzel R. Quintanilha Luiz Fernando Hidaka Isao Marumoto Yoshio Saeki Issei Uchida Koichi Yamasaki Takahiro Tani Kenji Taura Yasuho Fujii Yasuhiko Nishina Hiroshi Okita Kiwamu Sakaida Isao Publishers : Mary Ann Liebert
山口医学 Volume 63 Issue 1 pp. 53 - 60
Discovery medicine Volume 14 Issue 74 pp. 7 - 12
Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy
Journal of gastroenterology
Creators : Terai Shuji Tanimoto Haruko Maeda Masaki Zaitsu Junichi Hisanaga Takuro Iwamoto Takuya Fujisawa Koichi Mizunaga Yuko Matsumoto Toshihiko Urata Yohei Marumoto Yoshio Hidaka Isao Ishikawa Tsuyoshi Yokoyama Yuichiro Aoyama Koji Tsuchiya Masako Takami Taro Omori Kaoru Yamamoto Naoki Segawa Makoto Uchida Koichi Yamasaki Takahiro Okita Kiwamu Sakaida Isao Publishers : Springer international | Springer-Verlag
Senescence marker protein 30 (SMP30)/regucalcin (RGN) expression decreases with aging, acute liver injuries and tumors in zebrafish
Biochemical and biophysical research communications Volume 414 Issue 2 pp. 331 - 336